PMCB (PharmaCyte Biotech) Total Stockholders Equity: $39.40 Mil (As of Jan. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PMCB PharmaCyte Biotech Inc PMCB
32 GF Score
Price $0.58
! 2 Warning Signs
View Full Analysis

What is PharmaCyte Biotech Total Stockholders Equity?

PharmaCyte Biotech PMCB -3.19% 32 Total Stockholders Equity is $39.40 Mil as of Jan. 2026. GuruFocus rates PMCB with a GF Score™ of 32/100. The stock has 2 warning signs investors should review.

PharmaCyte Biotech's Total Stockholders Equity for the quarter that ended in Jan. 2026 was $39.40 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. PharmaCyte Biotech's Book Value per Share for the quarter that ended in Jan. 2026 was $3.59. The ratio of a company's debt over equity can be used to measure how leveraged this company is. PharmaCyte Biotech's Debt-to-Equity for the quarter that ended in Jan. 2026 was 0.00.

PharmaCyte Biotech  (NAS:PMCB) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

PharmaCyte Biotech's Book Value per Share for the quarter that ended in Jan. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(39.402-0.872)/10.736
=3.59

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

PharmaCyte Biotech's Debt-to-Equity for the quarter that ended in Jan. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 39.402
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaCyte Biotech Total Stockholders Equity Related Terms

PharmaCyte Biotech Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for PharmaCyte Biotech's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaCyte Biotech Total Stockholders Equity Chart

PharmaCyte Biotech Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.68 89.92 72.69 39.52 51.89

PharmaCyte Biotech Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 40.25 51.89 43.59 36.55 39.40
PMCB
32GF Score
PharmaCyte Biotech Inc PMCB
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $39.40 Mil mean?
PharmaCyte Biotech (PMCB) has a Total Stockholders Equity of $39.40 Mil as of Jan. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for PharmaCyte Biotech and its competitors.
Is PharmaCyte Biotech's Total Stockholders Equity too high?
PharmaCyte Biotech's current Total Stockholders Equity is $39.40 Mil. Overall, PharmaCyte Biotech has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCyte Biotech's Total Stockholders Equity compare to NIKI and IMNN?
PharmaCyte Biotech's Total Stockholders Equity of $39.40 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for PharmaCyte Biotech and its competitors. PharmaCyte Biotech's current Total Stockholders Equity is $39.40 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCyte Biotech stock overvalued right now?
PharmaCyte Biotech (PMCB) has a current Total Stockholders Equity of $39.40 Mil. The current Total Stockholders Equity is $39.40 Mil. PharmaCyte Biotech's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For PharmaCyte Biotech (PMCB), the current Total Stockholders Equity is $39.40 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmaCyte Biotech Business Description

Address 3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV, USA, 89169
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
32GF Score

Get the complete analysis for PMCB

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.58
Price